omniture
KAZIA THERAPEUTICS LIMITED.

Latest News

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2021-03-02 07:00 2981

Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-12-10 12:51 5244

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-12-09 07:49 2189

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

SYDNEY, Nov. 18, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-11-18 07:39 2116

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-10-16 07:30 11679

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-09-22 09:21 6792

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-08-24 09:14 5673

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-08-20 08:35 7784

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-08-07 08:30 13056

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

SYDNEY, June  22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2020-06-22 12:39 3275

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2020-06-01 08:45 4128

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2020-04-07 20:00 3078

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2019-12-11 08:41 5540

Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2019-11-25 07:00 1423

Kazia Raises A$4.0 Million to Progress R&D Programs

SYDNEY, Oct. 28, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2019-10-28 10:16 6292

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeuti...

2019-09-13 20:00 6582

St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Aust...

2019-09-12 21:10 6894

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austr...

2019-07-22 09:08 2449

Kazia calls for greater awareness of the deadliest brain cancer in the US

SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused ...

2019-07-17 20:00 7283

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

SYDNEY, May 20, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Austra...

2019-05-20 11:41 2552
12345